September 30, 2026 05:27 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
SIR row: Supreme Court to hear plea against CEC Gyanesh Kumar next week | Sambhal violence case: SC quashes key accused Mulla Afroz's NSA detention, slaps Rs 10 lakh cost on UP govt | Nandigram bypoll twist: Calcutta HC grants interim bail to Congress candidate Milan Pradhan till Oct 21 | Myanmar military airstrike horror: 49 killed, 58 injured as bombs hit crowded Rakhine market | Britain reopens refugee routes for Afghans, Palestinians as immigration and integration battle intensifies | New York Times executive shot dead: Elderly in-laws arrested amid bitter family feud over his 'trans' identity | Vijay's TVK makes Bengal entry: First party office opens in Purba Bardhaman amid state's political shake-up | SRFTI clash erupts over ABGP event: Students allege assault; BJP calls it ‘ugly face of Leftists’ | 'Asif bhai gun nikal': 17-year-old's chilling account of men posing as cops raping her in South Delhi park | Indian passport rules changed: New validity, fees for children and adults explained
Corona Remedies
Corona Remedies listed at 38% premium. Photo: ChatGPT

Corona Remedies storms Dalal Street! Shares list at 38% premium on debut

| @indiablooms | Dec 15, 2025, at 11:19 am

Mumbai/IBNS: Pharmaceutical firm Corona Remedies made a strong debut on the stock market on Monday, listing at a 38% premium over its IPO price on the National Stock Exchange (NSE), media reports said.

The company’s shares were listed at ₹1,470 apiece on the NSE, marking a 38.42% premium over the issue price.

On the BSE, the stock debuted at ₹1,452 per share, a 36.72% premium.

The ₹655.37-crore IPO, which was entirely an offer for sale, had a price band of ₹1,008–1,062 per share and was open for subscription from December 8 to 10.

Headquartered in Ahmedabad, Gujarat, Corona Remedies is an Indian pharmaceutical company with a strong presence in branded generics, catering to both chronic and acute therapy segments.

The robust listing underscored strong investor confidence in the company’s growth outlook and financial performance, reflecting sustained demand for quality pharma IPOs in the Indian market.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.